The Food and Drug Administration (FDA) has expanded the approval of Rebinyn® (coagulation factor IX [recombinant], GlycoPEGylated) to include use in adults and children with hemophilia B for routine prophylaxis to reduce the frequency of bleeding episodes. The recombinant DNA-derived coagulation Factor IX concentrate is also approved for on-demand treatment and control of bleeding episodes and for perioperative management of bleeding.

The approval for routine prophylaxis was supported by data from the main phase of the adult/adolescent and pediatric previously treated patients (PTP) trials. A PTP was defined as a patient with a history of at least 150 exposure days to other Factor IX products (adolescent/adult patients) or 50 exposure days to other Factor IX products (pediatric patients), and no history of inhibitors. Patients 0 to 65 years of age received Rebinyn 40 IU/kg once weekly for approximately 52 weeks.

Results showed an overall median annualized bleeding rate (ABR) of 1.04, 2.00, and 0 in patients 13 years of age and older, 7 to 12 years of age, and 6 years and younger, respectively. The most common adverse reactions reported with Rebinyn were itching and injection site reactions.

Continue Reading

“In clinical studies, when adults and adolescent people living with hemophilia B were given prophylactic treatment with Rebinyn, patients experienced factor IX activity in the same range as people without hemophilia (above 40%) for nearly 80% of the week,” said Allison P. Wheeler, MD, MSCI, Vanderbilt University Medical Center, Nashville, TN. “This is supported by the World Federation of Hemophilia acknowledgement that replacement therapy with extended half-life FIX allows for more ambitious prophylaxis.”

Rebinyn is available as a lyophilized powder in single-dose vials containing 500 IU, 1000 IU, and 2000 IU.

References

  1. Novo Nordisk receives FDA approval for Rebinyn® for routine prophylaxis to prevent bleeding in people living with hemophilia B. News release. Novo Nordisk. July 29, 2022. Accessed August 2, 2022. https://www.novonordisk-us.com/content/nncorp/us/en_us/media/news-archive/news-details.html?id=127305
  2. Rebinyn. Package insert. Novo Nordisk; 2022. Accessed August 2, 2022. https://www.novo-pi.com/rebinyn.pdf

This article originally appeared on MPR

Topics:

Bleeding Disorders Hemophilia